Podcast: Play in new window
Dr. Jeffrey Bluestone is the CEO and President of Sonoma Biotherapeutics, a San Francisco and Seattle-based company leveraging the properties of regulatory T cells to create living cell therapies that restore the immune system back to its balanced, fully functioning state.
Dr. Jeffrey Bluestone is the CEO and President of Sonoma Biotherapeutics, which is leveraging the properties of regulatory T cells to create living cell therapies that restore the immune system…
Dr. Jenny P. Y. Ting is a William R Kenan Jr. Distinguish Professor at the University of North Carolina at Chapel Hill. Her lab studies the biological effects of NLR…
Podcast: Play in new window
Dr. Christopher Klebanoff is an Principal Investigator and Attending Physician at the Memorial Sloan Kettering Cancer Center. His research focuses on cell-based cancer immunotherapies, T cell receptors, and the therapeutic targeting of shared cancer neoantigens. Using single-cell sequencing, biophysical measurements of T cell receptor affinity, genetic engineering, and structural immunobiology, the Klebanoff lab aims to adapt adoptive T cell transfer for advanced solid tumors.
Podcast: Play in new window
Dr. James Crowe is the Director of the Vanderbilt Vaccine Center. Their group uses a very broad array of techniques including molecular and cellular biology, state-of-the-art imaging and flow cytometry, bioinformatics, and bioengineering approaches to attack the scientific problems that are of interest to them: major human pathogens.
